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ABSTRACT 
The aims of this study were to evaluate the effects of caffeine supplementation on sprint 
cycling performance and to determine if there was a dose-response effect. Using a 
randomised, double-blind, placebo-controlled design, 17 well-trained males (age, height, 
and body mass: 24  6 years, 1.82  0.06 m, and 82.2  6.9 kg, respectively) completed 
seven maximal 10 s sprint trials on an electromagnetically-braked cycle ergometer. Apart 
from Trial 1 (familiarisation), all trials involved subjects ingesting a gelatine capsule 
containing either caffeine or placebo (maltodextrin) one hour prior to each sprint. To 
examine dose-response effects, caffeine doses of 2, 4, 6, 8, and 10 mgkg body mass-1 
were used. There were no significant (p ≥ 0.05) differences in baseline measures of 
plasma caffeine concentration prior to each trial (grand mean: 0.14  0.28 g.ml-1). There 
was, however, a significant supplement  time interaction (p < 0.001), with larger 
caffeine doses producing higher post-supplementation plasma caffeine levels. In 
comparison with placebo, caffeine had no significant effect on peak power (p = 0.11), 
mean power (p = 0.55), or time to peak power (p = 0.17). There was also no significant 
effect of supplementation on pre-trial blood lactate (p = 0.58), but there was a significant 
time effect (p = 0.001), with blood lactate reducing over the 50 minute post-
supplementation rest period from 1.29  0.36 mmolL-1 to 1.06  0.33 mmolL-1. The 
results of this study show that caffeine supplementation has no effect on short-duration 
sprint cycling performance, irrespective of the dosage used.                   
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INTRODUCTION 
Caffeine, a trimethylxanthine, is one of the most commonly consumed drugs in 
the world, with no apparent long-term adverse health effects (17). Despite being 
previously on the World Anti-Doping Agency (WADA) list of controlled substances (> 
12 gml-1 in urine was considered a doping offence), its removal in 2004 opened up the 
potential for athletes to exploit its ergogenic potential. Research into the effects of 
caffeine on athletic performance has been focused largely around endurance exercise, 
particularly since early research hypothesised a glycogen-sparing mode-of-action. 
Although evidence of a positive effect on endurance is considerable (5), the shift to a 
central nervous system mediated mode of action (via adenosine receptor antagonism) has 
led researchers to also consider the effects of caffeine on shorter and more intense 
exercise paradigms. Research into the effects of caffeine on speed-endurance events (60 – 
180 s) and multiple sprint events tends to support a positive effect (8). Indeed, in a recent 
investigation from this laboratory, caffeine supplementation was found to increase sprint 
performance in the early stages of a 12  30 m multiple sprint test (10). Moreover, the 
magnitude of the improvement in fastest sprint time was evenly distributed across each 
10 m split, suggesting potential benefits over longer sprint durations and single sprint 
events. In contrast, research into the effects of caffeine on single bouts of brief maximal 
work (primarily focused on 30 s Wingate anaerobic tests) generally, though not always 
(1,21), fails to show any performance effects (3,7,14,15,16,20,22). However, the 
possibility of pacing strategies influencing sprint durations of around 30 s, even in well-
trained individuals, is a confounding factor (23). Indeed, several factors such as: poor 
sample sizes; use of untrained participants; failure to test resting plasma/urine caffeine 
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concentrations; inadequate placebos; and the use of fixed rather than relative caffeine 
doses, may explain why research into the effects of caffeine on high-intensity exercise 
has many discrepancies.  
 
The primary aim of the present study was to address the aforementioned 
methodological limitations in order to investigate the effects of acute caffeine ingestion 
on brief (10 s) maximal sprint cycling performance. In addition, the study aimed to 
investigate whether, as with endurance performance, effects followed a dose-related 
response (4,13). Finally, several investigations have observed elevations in blood lactate 
following caffeine supplementation. If those elevations cannot be explained by a 
caffeine-induced increase in lactate production by the working muscles (12), then 
supplementation should lead to an increase in resting blood lactate concentrations. 
Therefore, a final aim of the present study was to investigate the effects of caffeine 
supplementation on resting blood lactate concentrations. 
 
METHODS 
Experimental Approach to the Problem 
All subjects completed seven maximal 10 s sprint trials on an electromagnetically-
braked cycle ergometer (Lode Excalibur Sport, Groningen, Holland), which was fitted 
with standard pedals, toe-clips, and straps, and interfaced with a computer to enable high-
frequency logging of the flywheel angular velocity. Trial 1 was a familiarisation test to 
limit the effects of learning on the outcome of the experiment and involved no blood 
sampling. In the remaining trials, which were randomised and conducted in a double-
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blind manner, subjects consumed a gelatine capsule containing either 2, 4, 6, 8, or 10 
mgkg bm1 of caffeine (My Protein, Manchester, UK), or the same volume (4 mgkg 
bm1) and colour of placebo (maltodextrin: My Protein, Manchester, UK). All trials were 
completed at approximately the same time of day with a minimum of 48 hours between 
each. Subjects were instructed to maintain their normal diet throughout the testing period, 
to avoid food and drink in the hour before testing, and to avoid strenuous exercise 24 
hours prior to each trial. Subjects were provided with a list of dietary sources of caffeine 
and asked to refrain from consuming these 48 hours prior to each trial. A questionnaire 
was used to establish typical daily caffeine consumption. 
 
Subjects 
Seventeen male strength & conditioning and sport science students volunteered 
for the study which was approved by St Mary’s University College Ethics Committee. 
Prior to testing, subjects received written and verbal instructions regarding the nature of 
the investigation and completed a training history questionnaire, which indicated that all 
had been actively involved in sport for approximately 12 years. Times spent training and 
competing each week were reported as 8.8  7.2 hours and 3.9  4.2 hours, respectively. 
Prior to commencement of the study, all subjects completed a health-screening 
questionnaire and provided written informed consent. Means ± standard deviation for 
age, height, body mass (bm), and body fat (9) of the subjects were: 24  6 years, 1.82  
0.06 m, 82.2  6.9 kg, and 13.5  3.4%, respectively. 
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Procedures 
All testing was conducted in a laboratory which was thermostatically controlled at 
18C. On arrival at the testing facility, and after approximately five minutes of seated 
rest, resting blood samples (~ 5 ml) were drawn from a branch of the basilic vein and 
collected in plain siliconised tubes. At the same time, blood samples were obtained from 
the earlobe via capillary puncture for the evaluation of blood lactate. Subjects then 
consumed the supplement after which they rested for 50 minutes before the same blood 
sampling procedures were repeated. Venous blood samples were allowed to clot at room 
temperature before being centrifuged at 2000 rpm for 20 minutes, with subsequently 
decanted serum samples frozen at 20C until analysed for caffeine and primary 
metabolite content using high-performance liquid chromatography (HPLC). Capillary 
blood samples were analysed for lactate content using an automated analyser (Biosen C-
Line, EKF Diagnostic, Ebendorfer Chaussee 3, Germany). The analyser was calibrated 
before all trials in accordance with the manufacturer’s instructions.  
 
After blood sampling procedures were completed, subjects performed a 
standardised warm-up comprising 3.5 minutes of cycling at 120 W using a cadence of 80 
rpm after which subjects were asked to indicate on a 20 cm visual analogue scale 
(ranging from ‘not ready’ to ‘very ready’) their perceived readiness to perform the 
forthcoming 10 s sprint. Subjects then performed two 5 s maximal practice sprints 
interspersed with 30 s of passive recovery, followed by another minute of cycling at 120 
W (see Figure 1). The saddle height and handlebar position for each subject were 
determined before the first trial and remained constant for all subsequent trials. On 
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completion of the warm up and starting from a stationary position, subjects performed a 
10 s maximal sprint against a torque factor of 0.7  bm. Subjects were verbally 
encouraged to give maximal effort during all trials. After each trial, subjects completed a 
cool-down by cycling at 120 W for a minimum of two minutes. 
 
FIGURE 1 ABOUT HERE 
 
Statistical Analyses  
All data were analysed using the Statistical Package for the Social Sciences (SPSS 
Inc., Chicago, IL). Measures of centrality and spread are presented as means ± standard 
deviation. The effects of supplementation on serum caffeine concentrations and blood 
lactate were analysed using a two-way (time × dose) ANOVA. The effects of caffeine 
dose on perceived readiness and on key sprint performance outcomes of peak power, 
mean power, and time to peak power were analysed using a one-way ANOVA. α was set 
at 0.05 for all comparisons and significant effects were followed up using Bonferroni-
adjusted post hoc analyses. The above analyses provided 95% confidence limits for all 
outcomes.   
 
RESULTS 
Analysis of the caffeine questionnaire data revealed that normal mean daily 
caffeine consumption of the subjects was 261 ± 224 mg (range: 10 – 677 mg). Analysis 
of the serum data (Table 1) revealed significant effects of time (F(1,16) = 297.64, p < 
0.001), dose (F(2.7, 43.3) = 32.89, p < 0.001), and time × dose (F(2.7, 42.7) = 33.48, p < 0.001). 
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Post hoc analyses showed that there were no significant differences in baseline serum 
caffeine concentrations obtained prior to each trial. In contrast, apart from placebo (p = 
0.299), significant increases in serum caffeine concentrations were observed between 
baseline and post-supplementation samples (p < 0.001). The time × dose interaction 
supported a dose-response effect of supplementation with higher doses producing higher 
serum caffeine concentrations; though not all post hoc comparisons were statistically 
significant (see Table 1). Blood lactate decreased significantly (F(1,16) = 18.32, p < 0.001) 
from baseline to post-supplementation (mean change: 0.22 mmol∙L-1; 95% likely range: 
0.11 to 0.34 mmol∙L-1); but there was no effect of caffeine dose (F(5, 80) = 0.76, p = 
0.581), and no time × dose interaction (F(5,80) = 1.74, p = 0.135) (Table 1). There was a 
significant effect of supplementation on perceived readiness (F(5,80) = 5.30, p < 0.001), 
with placebo resulting in significantly lower scores than the 2, 8, and 10 mg caffeine 
doses (Table 1). Supplementation had no significant effect on sprint performance 
measures of peak power (F(5,80) = 1.88, p = 0.108), mean power (F(5,80) = 0.80, p = 0.552), 
or time to peak power (F(3.63,58.15) = 1.68, p = 0.172) (see Table 2). 
 
TABLES 1 & 2 ABOUT HERE 
 
DISCUSSION 
The principal aim of this study was to examine the effects of caffeine 
supplementation on short-duration maximal-intensity sprint cycling. The main finding 
was that caffeine had no significant effect on any of the measures of sprinting 
performance. The absence of any significant effect of caffeine on short-duration (≤ 30 s) 
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sprinting performance confirms a number of previous reports (3,7,14,15,16,20,22), but 
contrasts with others (1,21). Though the majority of studies support the absence of an 
effect of caffeine on sprinting performance, it is difficult to explain why this is not always 
the case. However, the fact that there was no dose-response effect of caffeine on 
performance suggests that between-protocol differences in dosing strategies are unlikely 
to be a confounding factor. Indeed, there are no common factors that explain the above 
discrepancies, though a failure to measure resting serum or urine caffeine concentrations 
in several studies (1,7,14,15,16,22) is a concern. 
 
One of the biggest problems when conducting research into responses to caffeine 
supplementation is that of blinding subjects to the treatment. Given the pronounced side 
effects of ‘jitteriness’ and ‘nervousness’ that generally accompany acute caffeine 
administration (19), it is often the case that subjects are able to determine when they have 
taken the supplement. Moreover, manifestation of those same side effects makes it 
difficult for researchers to also maintain a blind perspective. In the present study, 
differences in perceived readiness scores between caffeine and placebo trials suggests 
that subjects were aware of when they had taken caffeine. However, despite this, subjects 
seemed unable to identify differences between the various doses used. Moreover, the 
absence of any subsequent effect of caffeine on performance suggests that knowledge of 
the supplement did not influence their motivation to give a maximal effort. Whilst the 
same may not have been the case if the duration of the sprints had been extended (23), the 
absence of an effect of caffeine on most 30 s sprint trials (3,7,14,15,16), diminishes the 
possibility of a placebo effect (2) influencing the results. 
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A secondary aim of the present study was to examine the effects of caffeine on 
resting blood lactate concentration. If, as reported, caffeine has no effect on lactate 
release by the working muscles (6,12), then, since many studies have shown a caffeine-
induced increase in blood lactate during constant-intensity exercise (11), an increase in 
blood lactate would be expected during resting conditions. However, the results of the 
present study showed that regardless of the dosage used, caffeine had no significant effect 
on resting blood lactate; indeed, values significantly reduced across the 50 minute pre-
trial resting period. Whilst it is possible that subtle differences in exercise intensity as a 
result of caffeine supplementation could explain many of the aforementioned elevations 
in blood lactate, more research is needed to clarify. 
 
In summary, the results of this study suggest, in conjunction with a number of 
previous reports, that caffeine supplementation has no significant effect on short-duration 
(≤ 30 s) sprinting performance. Moreover, the absence of any effect on performance does 
not appear to be dose related. Given that caffeine appears to exert its effect via a central 
mechanism, and that the effects of caffeine on endurance exercise are well established, 
further research with rigorous methodological control is required to clarify the duration of 
exercise for which caffeine ceases to be ergogenic. Finally, if caffeine does indeed have 
no effect on sprinting performance, it is difficult to reconcile the positive effects of 
caffeine in some tests of repeated sprint performance, particularly since such effects have 
been observed from the start of each protocol (10,18).  
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PRACTICAL APPLICATIONS 
The removal of caffeine from the WADA list of controlled substances in 2004 opened up 
opportunities for athletes to exploit its ergogenic effects. Nevertheless, although previous 
research supports positive effects in endurance exercise, the results of this study show 
that caffeine has no effect on short-duration sprinting performance, regardless of the 
dosage used.    
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Figure 1. Schematic of the experimental protocol to investigate the effects of caffeine 
supplementation on 10 s sprint cycling performance. 
 
Table 1. The effects of various doses of caffeine supplementation on pre-sprint measures of 
serum caffeine concentration, blood lactate and perceived readiness. Values are means  standard 
deviation.   
Caffeine dose 
(mgkg bm-1) 
Serum caffeine concentration (gml-1) Blood lactate (mmolL-1) Readiness 
score (%) Pre-
supplementation  
Post-
supplementation 
Pre-
supplementation  
Post-
supplementation 
Placebo 0.20  0.32a 0.19  0.30 1.25  0.36
f
 1.04  0.39
g
 46  19
i
 
2 0.09  0.16a 3.68  2.01 1.20  0.30
f
 1.05  0.33
g
 67  15
h
 
4 0.19  0.36a 9.06  3.72
b
 1.28  0.39
f
 1.03  0.32
g
 65  19
hi
 
6 0.15  0.24a 10.72  4.72
bc
 1.23  0.34
f
 1.14  0.33
g
 63  23
hi
 
8 0.04  0.10a 14.28  5.65
cd
 1.42  0.39
f
 1.14  0.35
g
 74  13
h
 
10 0.20  0.39a 17.6  8.14
d
 1.34  0.41
f
 0.98  0.30
g
 70  21
h
 
Note: bm = body mass; mean values with the same superscript in each column are not 
significantly different (p ≥ 0.05). 
 
Table 2. The effects of caffeine supplementation on measures of maximal 10 s sprint cycling 
performance. Values are means  standard deviation. 
Caffeine dose (mgkg bm-1) Peak power (W) Mean power (W) Time to peak power (s) 
Placebo 1133  186 767  117 4.7  1.1 
2 1133  200 769  113 4.6  1.2 
4 1147  199 784  125 4.5  1.4 
6 1111  204 772  115 4.3  1.3 
8 1148  194 774  104 4.4  1.0 
10 1141  195 776  105 4.2  1.0 
 Note: bm = body mass 
 
